(Total Views: 462)
Posted On: 07/08/2022 9:45:20 PM
Post# of 157825
Yea why would we want to fund a phase 3?
Oh we let NASH go to a third party ? Who cares there’s only 1000009 other indications.
Yea I’m with management. Focus on the BLA and look for partnerships for the other trials we need to do.
Almost all of are problems can be solved once the BLA is completed. We will know more before the year is over. It’s actually possible it gets filed this year.
So yes nobody wants more shares issued. But who knows we might not even use them. If we don’t authorize more shares then we are in a bad spot to negotiate.
I think we are in a great spot to negotiate as long as the lights are on. We have two trials that hit end points this year. mTNBC and NASH. One or both will most definitely get a partners. That’s a no brainer. Don’t let people convince you that this isn’t on the table. I call bullshit.
We also have the basket trial that’s almost done correct?
Oh we let NASH go to a third party ? Who cares there’s only 1000009 other indications.
Yea I’m with management. Focus on the BLA and look for partnerships for the other trials we need to do.
Almost all of are problems can be solved once the BLA is completed. We will know more before the year is over. It’s actually possible it gets filed this year.
So yes nobody wants more shares issued. But who knows we might not even use them. If we don’t authorize more shares then we are in a bad spot to negotiate.
I think we are in a great spot to negotiate as long as the lights are on. We have two trials that hit end points this year. mTNBC and NASH. One or both will most definitely get a partners. That’s a no brainer. Don’t let people convince you that this isn’t on the table. I call bullshit.
We also have the basket trial that’s almost done correct?


Daniel Rizzo
Founder & CEO | FireGate Biotech™
AI Platform: Lux Veritas™
Federal Whistleblower Case References
• HHS & SEC Whistleblower ID – HL-1412396
• DOJ Investigation Report / Whistleblower ID – 20250705-0001
• NIH Case Reference – CS1137565 ( IC IG / 50 U.S.C. § 3033 )
Website: FireGateBiotech.com
Headquarters: Washington, DC
Mailing & correspondence: 1930 18th St NW Suite B2 PMB 2161, Washington DC 20009
(For official updates and correspondence — I will no longer be posting here or responding via DMs)
Contact FireGate Biotech
Principal Investigator:
FG001|FG002|FG003
https://firegatebiotech.com/2025
FG-001: Integrated Triplet Immunotherapy for Functional HIV Cure
FG-002: Triplet Immunologic Modulation in Oncology — NF-κB / IL-1Ra Axis
FG-003: Neuro-Immune Repair Triplet — Concept and Combination Framework
CCR5 Antagonists & Triplet Immunotherapy Synergy in HIV
HIV Cure Pathways — Functional-Cure Framework Overview
FG-003 Neuro-Immune Repair Triplet — IP & Combination Strategy
— Jeremiah 51:36
Founder & CEO | FireGate Biotech™
AI Platform: Lux Veritas™
Federal Whistleblower Case References
• HHS & SEC Whistleblower ID – HL-1412396
• DOJ Investigation Report / Whistleblower ID – 20250705-0001
• NIH Case Reference – CS1137565 ( IC IG / 50 U.S.C. § 3033 )
Website: FireGateBiotech.com
Headquarters: Washington, DC
Mailing & correspondence: 1930 18th St NW Suite B2 PMB 2161, Washington DC 20009
(For official updates and correspondence — I will no longer be posting here or responding via DMs)
Contact FireGate Biotech
Principal Investigator:
FG001|FG002|FG003
https://firegatebiotech.com/2025
FG-001: Integrated Triplet Immunotherapy for Functional HIV Cure
FG-002: Triplet Immunologic Modulation in Oncology — NF-κB / IL-1Ra Axis
FG-003: Neuro-Immune Repair Triplet — Concept and Combination Framework
CCR5 Antagonists & Triplet Immunotherapy Synergy in HIV
HIV Cure Pathways — Functional-Cure Framework Overview
FG-003 Neuro-Immune Repair Triplet — IP & Combination Strategy
— Jeremiah 51:36